Skip to main content

Breadcrumb

  1. Home

Comprehensive analysis of natural killer cell-associated markers using MultiOmyx immunofluorescence assay

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Comprehensive analysis of natural killer cell-associated markers using MultiOmyx immunofluorescence assay

Characterizing CD39 and CD73 cell subtypes in the tumor microenvironment using MultiOmyx immunofluorescence assay

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Characterizing CD39 and CD73 cell subtypes in the tumor microenvironment using MultiOmyx immunofluorescence assay

Bridging the gap between targeted NGS and FISH gene-level CNV detection capabilities in hematologic malignancies

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Bridging the gap between targeted NGS and FISH gene-level CNV detection capabilities in hematologic malignancies

Spatial Analysis of Genomic Signatures on Colorectal Cancer Pathogenesis Using the NanoString GeoMx® Digital Spatial Profiler

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Spatial Analysis of Genomic Signatures on Colorectal Cancer Pathogenesis Using the NanoString GeoMx® Digital Spatial Profiler

Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer

Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC)

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC)

A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD)

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD)

LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer

Circulating tumor DNA (ctDNA) monitoring in breast cancer patients receiving neoadjuvant palbociclib and endocrine therapy. A secondary analysis of the NeoRHEA phase 2 study

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Circulating tumor DNA (ctDNA) monitoring in breast cancer patients receiving neoadjuvant palbociclib and endocrine therapy. A secondary analysis of the NeoRHEA phase 2 study

Optimization of an Integrated MultiOmyx-RNAscopehyperplexassay for co-detection and characterization of multiple protein and RNA biomarkers within the tumor microenvironment (TME)

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Optimization of an Integrated MultiOmyx-RNAscopehyperplexassay for co-detection and characterization of multiple protein and RNA biomarkers within the tumor microenvironment (TME)

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • …
  • Next page Next
  • Last page Last
Subscribe to